Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: Mechanism of immune evasion

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Lundholm, Marie ^a   Schröder, Mona ^a   Nagaeva, Olga ^a   Baranov, Vladimir ^a   Widmark, Anders ^a   Mincheva Nilsson, Lucia ^a   Wikström, Pernilla ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD63 ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; HLA ANTIGEN CLASS 1; KLRK1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; SIGNAL PEPTIDE;

ARTICLE; BLOOD SAMPLING; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; ELECTRON MICROSCOPY; EXOSOME; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INCUBATION TEMPERATURE; LYMPHOCYTE; MALE; MEMBRANE MICROPARTICLE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN CONTENT; PROTEIN EXPRESSION; SUPERNATANT; TUMOR ESCAPE; TUMOR GROWTH; ULTRACENTRIFUGATION; WESTERN BLOTTING; CASTRATION; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; K562 CELL LINE; METABOLISM; MONONUCLEAR CELL; PATHOLOGY;

ANTIBODIES, MONOCLONAL; CASTRATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DOWN-REGULATION; EXOSOMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; K562 CELLS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MALE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROSTATIC NEOPLASMS;

EID: 84931033158     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108925     Document Type: Article

References (43)

1. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, et al. (2001) Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 166: 7309-7318.
2. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, et al. (2007) Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659.
3. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, et al. (2010) Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 107: 6328-6333.
4. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, et al. (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470 -1476.
5. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, et al. (2002) Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360: 295-305.
6. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C (2005) Exosomal-like vesicles are present in human blood plasma. Int Immunol 17: 879-887.
7. Huber V, Fais S, Iero M, Lugini L, Canese P, et al. (2005) Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 128: 1796-1804.
8. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, et al. (2006) Human tumorreleased microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 66: 9290-9298.
9. Filipazzi P, Burdek M, Villa A, Rivoltini L, Huber V (2012) Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol 22: 342-349.
10. Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, et al. (2008) Exosomes as a tumor immune escape mechanism: Possible therapeutic implications. J Transl Med 6: 37.
11. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, Lopez-Vazquez A, Lopez-Larrea C (2008) NKG2D ligands: Key targets of the immune response. Trends Immunol 29: 397-403.
12. Hayakawa Y, Smyth MJ (2006) NKG2D and cytotoxic effector function in tumor immune surveillance. Semin Immunol 18: 176-185.
13. Ljunggren HG (2008) Cancer immunosurveillance: NKG2D breaks cover. Immunity 28: 492-494.
14. Jamieson AM, Diefenbach A, McMahon GW, Xiong N, Carlyle JR, et al. (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17: 19-29.
15. Wu J, Song Y, Bakker AB, Bauer S, Spies T, et al. (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730 -732.
16. Gasser S, Orsulic S, Brown EJ, Raulet DH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190.
17. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, et al. (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Nad Acad Sci USA 96: 6879-6884.
18. Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, et al. (2006) Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 118: 1445-1452.
19. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, et al. (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114: 560 -568.
20. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
21. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, et al. (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102: 1389-1396.
22. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, et al. (2008) Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 180: 7249-7258.
23. Clayton A, Tabi Z (2005) Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 34: 206-213.
24. Hedlund M, Nagaeva O, Kargl D, Baranov V, Mincheva-Nilsson L (2011) Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One 6: e16899.
25. Hedlund M, Stenqvist AC, Nagaeva O, Kjellberg L, Wulff M, et al. (2009) Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 183: 340-351.
26. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, et al. (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195: 1303-1316.
27. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, et al. (2002) Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 270: 211-226.
28. Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z (2005) Induction of heat shock proteins in B-cell exosomes. J Cell Sci 118: 3631-3638.
29. Michaelsson J, Teixeira de Matos C, Achour A, Lanier LL, Karre K, et al. (2002) A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 196: 1403-1414.
30. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nat Med 18: 883-891.
31. Lanier LL (2001) A renaissance for the tumor immunosurveillance hypothesis. Nat Med 7: 1178-1180.
32. Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98: 11521-11526.
33. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171.
34. Ashiru O, Boutet P, Fernandez-Messina L, Aguera-Gonzalez S, Skepper JN, et al. (2010) Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA 008 that is shed by tumor cells in exosomes. Cancer Res 70: 481-489.
35. Lee JC, Lee KM, Kim DW, Heo DS (2004) Elevated TGF-betal secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172: 7335-7340.
36. Li H, Han Y, Guo Q, Zhang M, Gao X (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182: 240-249.
37. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, et al. (2003) Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 171: 6891-6899.
38. Salih HR, Holdenrieder S, Steinle A (2008) Soluble NKG2D ligands: Prevalence, release, and functional impact. Front Biosci 13: 3448-3456.
39. Fernandez-Messina L, Ashiru O, Boutet P, Aguera-Gonzalez S, Skepper JN, et al. (2010) Differential mechanisms of shedding of the glycosylphosphatidy-linositol (GPI)-anchored NKG2D ligands. J Biol Chem 285: 8543-8551.
40. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, et al. (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571 -580.
41. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, et al. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55: 219-237.
42. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, et al. (2005) Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11: 1010 -1020.
43. Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, et al. (2005) Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis 35: 169-173.